Aptose Biosciences Inc. (APTO) Analysts See $-0.13 EPS

March 21, 2018 - By Vivian Park

 Aptose Biosciences Inc. (APTO) Analysts See $ 0.13 EPS

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) to report $-0.13 EPS on March, 27 after the close.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.11 EPS previously, Aptose Biosciences Inc.’s analysts see 18.18 % EPS growth. The stock increased 3.44% or $0.12 during the last trading session, reaching $3.76. About 250,880 shares traded. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since March 21, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. H.C. Wainwright upgraded the stock to “Buy” rating in Thursday, September 7 report. The company was maintained on Wednesday, December 13 by H.C. Wainwright. RBC Capital Markets maintained Aptose Biosciences Inc. (NASDAQ:APTO) on Wednesday, November 11 with “Outperform” rating. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) earned “Hold” rating by H.C. Wainwright on Thursday, June 8. H.C. Wainwright maintained Aptose Biosciences Inc. (NASDAQ:APTO) on Wednesday, August 9 with “Hold” rating. The firm has “Neutral” rating given on Friday, November 20 by TH Capital. Roth Capital upgraded Aptose Biosciences Inc. (NASDAQ:APTO) rating on Monday, June 13. Roth Capital has “Buy” rating and $8 target. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, November 16 report. Roth Capital downgraded the stock to “Neutral” rating in Friday, November 20 report. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Buy” rating given on Wednesday, November 15 by H.C. Wainwright.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $109.98 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.